Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

计划入组 12 人 · 首次发布于 2020 年 8 月 13 日

IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

计划入组 30 人 · 首次发布于 2025 年 1 月 10 日

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

计划入组 31 人 · 首次发布于 2019 年 7 月 17 日

I-131-Apamistamab

Iomab-ACT

Apamistamab iodine I-131

Universitetet i Oslo

Norway

I-SHOU UNIVERSITY

Taiwan

i-SENS, Inc.

South Korea

I-131 Apamistamab Improves Durable Remission in Relapsed/Refractory AML Before Transplant

Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape

Iopofosine I 131 Shows Promise in Heavily Pretreated Waldenström Macroglobulinemia